Quarterly report [Sections 13 or 15(d)]

Segment Information - Schedule of Profit and Loss from Segments (Details)

v3.25.2
Segment Information - Schedule of Profit and Loss from Segments (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Research and Development Expense [Abstract]            
Personnel $ 12,001   $ 9,401   $ 23,366 $ 17,164
Clinical trials 9,070   5,313   17,581 9,735
Development services 4,197   4,112   7,765 8,459
Manufacturing of preclinical and clinical supplies 11,610   3,798   16,642 7,341
License of intellectual property 0   4   0 1,515
Other research and development costs [1] 760   799   1,302 1,167
General and administration expenses 8,268   6,852   16,386 12,929
Interest income (1,410)   (2,677)   (2,897) (5,661)
Interest expense 571   0   865 0
Other expense 61   0   61 0
Net loss $ 45,128 $ 35,943 $ 27,602 $ 25,047 $ 81,071 $ 52,649
[1] Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.